Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the commencement of an underwritten public offering valued at $200 million. The offering includes shares of its common stock and pre-funded warrants for those investors opting for them instead of the common stock. Additionally, Enliven may grant underwriters a 30-day option to purchase up to an extra $30 million in common stock. The offering is contingent on market conditions, with no assurance of completion or specific terms. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, and LifeSci Capital is acting as lead manager for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.